Bhatt DL, Steg PG, Mehta SR, et al. - Through The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study, a phase 3 randomized, double-blinded, placebo-controlled trial conducted in 1,315 sites in 42 countries on 11,154 patients 50 years or older, with T2D, who received anti-hyperglycemic drugs for at least 6 months, with stable coronary artery disease, researchers examined whether these patients would profit from treatment with aspirin plus ticagrelor. In individuals with diabetes, stable coronary artery disease, and former percutaneous coronary intervention (PCI), ticagrelor added to aspirin decreased cardiovascular death, myocardial infarction, and stroke, however, with progressed major bleeding. In that large, readily recognized population, ticagrelor gave a favorable net clinical advantage (more than in individuals without a history of PCI). Moreover, this impact exhibits that in individuals with diabetes and a history of PCI who have endured antiplatelet therapy, have increased ischaemic risk, and low bleeding risk, long-term therapy with ticagrelor in addition to aspirin should be taken into account.